BenevolentAl Therapeutics Pipeline and Triage
Both the Ulcerative Colitis and Crohn's Disease markets are
large, and expected to experience sizable growth
USD Millions
USD Millions
Ulcerative Colitis Market Size, 2019-2029, 7MM(1)
14000
12000
10000
8000
6000
4000
2000
0
6.1% CAGR
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Crohn's Disease Market Size, 2019-2029, 7MM (2)
14000
12000
10000
8000
6000
4000
5.6% CAGR
• Taken together, the 2019 UC and CD market sizes were
valued at approx. $14B across the 7 major markets,
expected to increase to approx $24B in total by 2029,
growing at a ~6% CAGR
Growth in the UC and CD markets is driven by:
Improved diagnosis and increasing prevalence
O Approval of numerous pipeline drugs (both small
molecules and biologics)
High treatment rates
High unmet need for safe & efficacious therapies
• Despite a competitive pipeline, there is opportunity to
differentiate BEN- 8744 as an oral small molecule with
a novel MoA based on safety, efficacy and through
pursuing a precision medicine approach
2000
0
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Source: (1) Global Data, Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2029: (2) GlobalData,
Crohn's Disease: Global Drug Forecast and Market Analysis to 2029. 7MM (7 Major Markets): EU5, US, Japan
AI
Benevolent 39View entire presentation